TK 002

Drug Profile

TK 002

Alternative Names: TK-002

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Takis
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Neoplasm antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Gastric cancer; Prostate cancer

Most Recent Events

  • 21 Jul 2016 Preclinical trials in Prostate cancer in Italy (unspecified route)
  • 21 Jul 2016 Preclinical trials in Gastric cancer in Italy (unspecified route)
  • 21 Jul 2016 Preclinical trials in Colorectal cancer in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top